September 24, 2024 03:20 PM EDT

FDA adcomm will reexamine approval of checkpoint inhibitors in two cancers based on key biomarker

Zachary Brennan

Senior Editor

The FDA’s Oncologic Drugs Advisory Committee will meet Thursday to discuss whether several immune checkpoint inhibitor drugs should come with narrower indications in two cancers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm will reexamine approval of checkpoint inhibitors in two cancers based on key biomarker

Zachary Brennan

Senior Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA ad­comm will re­ex­am­ine ap­proval of check­point in­hibitors in two can­cers based on key bio­mark­er

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA adcomm will reexamine approval of checkpoint inhibitors in two cancers based on key biomarker

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra